Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03441555 · ClinicalTrials.gov registry record · Phase 1
A Study of Venetoclax and Alvocidib in Patients With Relapsed/Refractory Acute Myeloid Leukemia
A Phase 1 study, sponsored by AbbVie.
- Completed
- Registry status
- Phase 1
- Development phase
- 36
- Enrollment target
NCT03441555 is a Phase 1 study that has completed, run by AbbVie. The registered enrollment target is 36 participants.
The verdict
NCT03441555, a Phase 1 study, has completed, sponsored by AbbVie.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 36 participants
- Enrollment target
Study Summary
An open-label, dose-escalation study to assess the safety and pharmacokinetics (PK), to determine the dose limiting toxicity (DLT) and the recommended Phase 2 dose (RPTD), and to assess the preliminary efficacy of alvocidib with venetoclax when co-administered in participants with relapsed or refractory (R/R) acute myeloid leukemia (AML).
Interventions
- DRUG Venetoclax
- DRUG Alvocidib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2018-05-30 |
| Est. Completion | 2021-01-25 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03441555
The ClinicalTrials.gov registry entry for NCT03441555 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AbbVie, which has 526 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Venetoclax is the first listed.
NCT03441555 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03441555 about?
NCT03441555 is a clinical study titled "A Study of Venetoclax and Alvocidib in Patients With Relapsed/Refractory Acute Myeloid Leukemia". An open-label, dose-escalation study to assess the safety and pharmacokinetics (PK), to determine the dose limiting toxicity (DLT) and the recommended Phase 2 dose (RPTD), and to assess the preliminary efficacy of alvocidib with venetoclax when co-administered in participants with relapsed or refrac...
What is the current status of trial NCT03441555?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 36 participants. The study started on 2018-05-30. Estimated completion is 2021-01-25.
What interventions are being tested in trial NCT03441555?
The interventions under investigation include: Venetoclax (DRUG), Alvocidib (DRUG).
Who is sponsoring clinical trial NCT03441555?
This trial is sponsored by AbbVie, which has 526 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.